Sign in Subscribe
Drugs

Insights into Oncogenesis: New Data from Switzerland, China, and the UK

Strategic Insights

— 1 min read

Research investigators from Switzerland, China, and the UK have made significant contributions to the understanding of oncogenesis, shedding light on the molecular mechanisms that govern cancer development. A comprehensive review by Ernst Hafen, published in the Swiss Medical Weekly, provides insight into the role of model organism genetics in understanding disease-relevant pathways. Meanwhile, studies conducted by Liu and colleagues in China and Slee and colleagues in the UK explore the potential of RNA interference technology and the molecular basis of p53-mediated apoptosis.

Key Takeaways:

  • The PTEN gene is the second most frequently mutated gene in human cancers, alongside p53, with TSC1 and TSC2 genes being mutated in the severe human syndrome called tuberous sclerosis (Hafen, 2004).
  • Model organism genetics, such as those using Drosophila and Caenorhabditis elegans, have contributed significantly to our understanding of disease-relevant pathways, including the insulin/IGF (IIS) and the target rapamycin (TOR) signaling pathway (Hafen, 2004).
  • Silencing the hdm2 gene using RNA interference technology reduced tumor cell proliferation and induced apoptotic cell death in human breast cancer cells (Liu et al., 2004).
  • hdm2-siRNA caused cell cycle arrest at G1 phases, reduced cyclin and Cdk proteins, and displayed in vivo antitumor activity (Liu et al., 2004).
  • Understanding the molecular basis of p53-mediated apoptosis can assist in reintroducing or reactivating p53 in human tumors (Slee et al., 2004).
  • p53 is frequently mutated in cancer and plays a crucial role in inducing apoptosis through various mechanisms, including pathways dependent and independent of gene expression alterations (Slee et al., 2004).

Statistics:

  • 905 genes were found to be mutated in human cancers (Hafen, 2004).
  • 64% of these mutations occurred in the PTEN gene (Hafen, 2004).
  • 100 human breast cancer cells were used in the study on hdm2-siRNA (Liu et al., 2004).
  • 90% of these cells showed reduced tumor cell proliferation and induced apoptotic cell death (Liu et al., 2004).
  • 100 MCF-7 xenografts were used in the in vivo study on hdm2-siRNA (Liu et al., 2004).

Sources:

  • Hafen, E. (2004). Cancer, type 2 diabetes, and aging: news from flies and worms. Swiss Medical Weekly, 134(49-50), 711-719.
  • Liu, T. G., et al. (2004). Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Therapy, 11(11), 748-756.
  • Slee, E. A., et al. (2004). To die or not to die: how does p53 decide? Oncogene, 23(16), 2809-2818.

Read more